- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05569343
Risk Factors for Achieving TO After LDPPHR-t
October 4, 2022 updated by: Renyi Qin, Tongji Hospital
Risk Factors for Achieving Textbook Outcome After Laparoscopic Duodenum-preserving Total Pancreatic Head Resection: a Retrospective, Observational Study
This is a single, retrospective, observational study to investigate the risk factors for achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Increasing numbers of benign or low-grade malignant neoplasms at the head of pancreas are being diagnosed due to computed tomography (CT), magnetic resonance imaging (MRI) and endoscopic ultrasonography (EUS).
Laparoscopic duodenum-preserving total pancreatic head resection (LDPPHR-t) has been accepted as a valid alternative treatment for benign and low-grade malignant neoplasms at the head of the pancreas.
The evaluation of quality of LDPPHR-t is important for surgeons to improve surgical quality.
Currently, the evaluation of surgical quality mainly depends on some single outcome indicators, such as morbidity, mortality, readmission rate, or hospital stay.
These single outcome indicators are difficult to accurately reflect the overall surgical quality and the composite outcome measures may be better than single outcome indicators.
Textbook outcome (TO) is such a composite concept and is realized when all the requirements after operation are achieved according to the "all or none" principle.
TO reflects the ideal surgical outcome and is a multidimensional measure for surgical quality assurance.
However, the risk factors for achieving TO after LDPPHR-t is unknown and no relevant articles have been reported so far.
The objective of study was to identify the risk factors for achieving TO after LDPPHR-t.
Study Type
Observational
Enrollment (Actual)
31
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Department of Biliary and Pancreatic Surgery, Tongji Hospital, Affiliated Tongji Medical College, Huazhong University of Science and Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients underwent laparoscopic duodenum-preserving total pancreatic head resection in the department of Biliary-Pancreatic Surgery of Tongji Hospital from May 2020 to December 2021.
Description
Inclusion Criteria:
- Patients underwent laparoscopic duodenum-preserving total pancreatic head resection.
- Aged 18 to 75 years old.
Exclusion Criteria:
- Peritoneal seeding or metastasis to distant sites.
- Incomplete clinical data.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Textbook outcome group
Achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection
|
This is an observational study without any intervention
|
|
Non-Textbook outcome group
Not achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection
|
This is an observational study without any intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative complications
Time Frame: up to 90 days
|
The postoperative complications were graded into mild complications and severe complications according to the Clavien-Dindo classification of surgical complications, including postpancreatectomy hemorrhage, postoperative pancreatic fistula , and bile leakage.
|
up to 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Operation time
Time Frame: Intraoperative
|
Operation time defined as the time from skin incision or trocar placement to complete skin closure
|
Intraoperative
|
|
Intraoperative blood loss
Time Frame: Intraoperative
|
Intraoperative blood loss recorded by the anesthetist using a vacuum system
|
Intraoperative
|
|
Readmission
Time Frame: up to 30 days
|
Readmission defined as any readmission within 30 days after discharge
|
up to 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Renyi Qin, MD, Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 8, 2020
Primary Completion (Actual)
December 23, 2021
Study Completion (Actual)
April 16, 2022
Study Registration Dates
First Submitted
October 3, 2022
First Submitted That Met QC Criteria
October 4, 2022
First Posted (Actual)
October 6, 2022
Study Record Updates
Last Update Posted (Actual)
October 6, 2022
Last Update Submitted That Met QC Criteria
October 4, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TJDBPS12
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Neoplasm of Uncertain Behavior Head
-
Karolinska University HospitalKarolinska InstitutetCompletedBenign Neoplasm of Liver and/or Biliary Ducts | Neoplasm of Uncertain Behavior of Biliary System | Benign Neoplasms of the Pancreas | Neoplasms of the PancreasSweden
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedColorectal Cancer | Neoplasm of Uncertain Malignant PotentialUnited States
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterCompletedProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Neoplasm of Uncertain BehaviorUnited States
-
Salzburger LandesklinikenRecruitingProstatic Neoplasm of Uncertain BehaviorAustria
-
Universitätsklinikum Hamburg-EppendorfCompletedChronic Pancreatitis | Resectable Pancreatic Head Neoplasm | Resectable Periampullary NeoplasmGreece, Germany, Italy
-
University of ZurichCompletedCancer of the Pancreatic HeadSwitzerland
-
University of Medicine and Pharmacy CraiovaTel-Aviv Sourasky Medical Center; Shengjing Hospital; Institut Paoli-Calmettes; University of Santiago de Compostela and other collaboratorsCompletedPancreatic Cancer | Secondary Malignant Neoplasm of Lymph Node | Benign Neoplasm of Lymph Nodes | Benign Pancreatic TumorsRomania
-
B. Braun Melsungen AGCompletedPlasma Volume Replacement | Surgery of the Pancreatic HeadGermany
-
Center Eugene MarquisCompletedLocally Advanced Malignant Neoplasm | Malignant Neoplasm of Head and NeckFrance
-
Johns Hopkins UniversityLustgarten FoundationCompletedPancreatic Mucinous-Cystic Neoplasm | Pancreatic Cysts | Intraductal Papillary Mucinous Neoplasm | Solid Pseudopapillary Tumour of the Pancreas | Cystic, Mucinous and/or Serous NeoplasmUnited States
Clinical Trials on No intervention
-
Hopital FochNot yet recruitingInterstitial Lung DiseaseFrance
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Huashan HospitalZhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Tongji Hospital; Qilu Hospital... and other collaboratorsRecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in VitroChina
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of Dublin, Trinity CollegeCompleted